MA31684B1 - Composition pharmaceutique contenant un antagoniste des canaux calciques de type dihydropyridine et son procédé de préparation - Google Patents
Composition pharmaceutique contenant un antagoniste des canaux calciques de type dihydropyridine et son procédé de préparationInfo
- Publication number
- MA31684B1 MA31684B1 MA32628A MA32628A MA31684B1 MA 31684 B1 MA31684 B1 MA 31684B1 MA 32628 A MA32628 A MA 32628A MA 32628 A MA32628 A MA 32628A MA 31684 B1 MA31684 B1 MA 31684B1
- Authority
- MA
- Morocco
- Prior art keywords
- preparation
- calcium channel
- channel antagonist
- pharmaceutical composition
- composition containing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
La présente invention porte sur la formulation de formes posologiques solides comprenant une quantité thérapeutiquement efficace d'un antagoniste des canaux calciques de type dihydropyridine, tels que la lercanidipine ou un sel de celle-ci, en combinaison avec du dioxyde de silicium colloïdal tel que l'aerosil' pour augmenter la biodisponibilité et améliorer la solubilité. L'invention porte également sur un procédé pour la préparation de ces formes posologiques par granulation par voie humide.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP2007/006517 WO2009012791A1 (fr) | 2007-07-23 | 2007-07-23 | Composition pharmaceutique contenant un antagoniste des canaux calciques de type dihydropyridine et son procédé de préparation |
Publications (1)
Publication Number | Publication Date |
---|---|
MA31684B1 true MA31684B1 (fr) | 2010-09-01 |
Family
ID=39223083
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA32628A MA31684B1 (fr) | 2007-07-23 | 2010-02-17 | Composition pharmaceutique contenant un antagoniste des canaux calciques de type dihydropyridine et son procédé de préparation |
Country Status (20)
Country | Link |
---|---|
EP (2) | EP2180883B1 (fr) |
JP (2) | JP5769963B2 (fr) |
KR (2) | KR101632079B1 (fr) |
CN (3) | CN101784260A (fr) |
AU (2) | AU2007356942B2 (fr) |
BR (2) | BRPI0721883A2 (fr) |
CA (2) | CA2691752C (fr) |
CO (1) | CO6290639A2 (fr) |
CR (1) | CR11285A (fr) |
EA (2) | EA021645B1 (fr) |
EC (1) | ECSP109984A (fr) |
ES (2) | ES2622495T3 (fr) |
MA (1) | MA31684B1 (fr) |
MX (2) | MX2010000856A (fr) |
MY (1) | MY153857A (fr) |
NZ (2) | NZ582648A (fr) |
TN (2) | TN2010000011A1 (fr) |
UA (2) | UA97161C2 (fr) |
WO (2) | WO2009012791A1 (fr) |
ZA (2) | ZA201000586B (fr) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008063888A2 (fr) | 2006-11-22 | 2008-05-29 | Plexxikon, Inc. | Composés modulant l'activité de c-fms et/ou de c-kit et utilisations associées |
WO2009012283A1 (fr) | 2007-07-17 | 2009-01-22 | Plexxikon Inc. | Composés et procédés pour la modulation des kinases et leurs indications |
CN101784260A (zh) * | 2007-07-23 | 2010-07-21 | 法尔玛赞公司 | 包含二氢吡啶钙通道拮抗剂的药物组合物及其制备方法 |
MX349923B (es) | 2009-04-03 | 2017-08-21 | Hoffmann La Roche | Composiciones del ácido propano-1-sulfónico {3-[5-(4-cloro-fenil)- 1h-pirrolo [2,3-b]-piridina-3-carbonil]-2,4-difluoro-fenil]-amida y el uso de las mismas. |
US8329724B2 (en) | 2009-08-03 | 2012-12-11 | Hoffmann-La Roche Inc. | Process for the manufacture of pharmaceutically active compounds |
ES2633317T3 (es) | 2009-11-06 | 2017-09-20 | Plexxikon, Inc. | Compuestos y métodos para la modulación de quinasas, e indicaciones para ello |
PT2672967T (pt) | 2011-02-07 | 2018-12-07 | Plexxikon Inc | Compostos e métodos de modulação da quinase e suas indicações |
AR085279A1 (es) | 2011-02-21 | 2013-09-18 | Plexxikon Inc | Formas solidas de {3-[5-(4-cloro-fenil)-1h-pirrolo[2,3-b]piridina-3-carbonil]-2,4-difluor-fenil}-amida del acido propano-1-sulfonico |
US9150570B2 (en) | 2012-05-31 | 2015-10-06 | Plexxikon Inc. | Synthesis of heterocyclic compounds |
WO2014078435A1 (fr) | 2012-11-14 | 2014-05-22 | W. R. Grace & Co.-Conn. | Compositions contenant un matériau biologiquement actif et un oxyde inorganique non ordonné |
GR1008554B (el) * | 2014-06-12 | 2015-09-03 | ΦΑΡΜΑΤΕΝ ΑΝΩΝΥΜΟΣ ΒΙΟΜΗΧΑΝΙΚΗ ΚΑΙ ΕΜΠΟΡΙΚΗ ΕΤΑΙΡΕΙΑ ΦΑΡΜΑΚΕΥΤΙΚΩΝ ΙΑΤΡΙΚΩΝ ΚΑΙ ΚΑΛΛΥΝΤΙΚΩΝ ΠΡΟΪΟΝΤΩΝ με δ.τ. ΦΑΡΜΑΤΕΝ, | Φαρμακευτικο σκευασμα περιεχον εναν αντιμυκητιασικο παραγοντα τριaζολης και μεθοδος για την παρασκευη αυτου |
CN104069500A (zh) * | 2014-06-20 | 2014-10-01 | 湖南天地恒一制药有限公司 | 一种包含乐卡地平的药物组合物 |
CN105168165B (zh) * | 2015-08-28 | 2018-06-26 | 江苏福邦药业有限公司 | 一种盐酸乐卡地平片及其制备方法 |
WO2018004379A1 (fr) * | 2016-07-01 | 2018-01-04 | Общество С Ограниченной Ответственностью "Гиостин" | Produit sous forme de capsule pour traiter des maladies d'articulations |
CN114533686B (zh) * | 2022-02-15 | 2023-10-20 | 湖南普道医药技术有限公司 | 一种二氢吡啶类药物的口服固体制剂及其制备方法 |
KR20240040407A (ko) * | 2022-09-21 | 2024-03-28 | 주식회사 종근당 | 사쿠비트릴ㆍ발사르탄 칼슘염을 포함하는 약제학적 조성물 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3720757A1 (de) * | 1987-06-24 | 1989-01-05 | Bayer Ag | Dhp-manteltablette |
US5209933A (en) * | 1990-01-10 | 1993-05-11 | Syntex (U.S.A.) Inc. | Long acting calcium channel blocker composition |
GB9025251D0 (en) * | 1990-11-20 | 1991-01-02 | Solomon Montague C | Nifedipine dosage forms |
BR9903490A (pt) * | 1998-12-15 | 2000-09-26 | Oscar Gold | Processo para a preparação de composições farmacêuticas de liberação programada contendo nimodipine, que permitem a liberação gradual e a manuntenção da ação terapeutica |
DE19944803A1 (de) * | 1999-09-20 | 2001-03-29 | Bayer Ag | Kombination von Dihydropyridinverbindungen und HMG-CoA-Reduktase-Inhibitoren und ihre Verwendung in Arzneimitteln |
US20040185097A1 (en) * | 2003-01-31 | 2004-09-23 | Glenmark Pharmaceuticals Ltd. | Controlled release modifying complex and pharmaceutical compositions thereof |
CN1901888A (zh) * | 2003-12-01 | 2007-01-24 | 生命周斯药物公司 | 包含乐卡地平的药物组合物 |
EP1694305B1 (fr) * | 2003-12-01 | 2019-10-16 | Recordati Ireland Limited | Compositions pharmaceutiques contenant de la lercanipidine |
MX2009002236A (es) * | 2006-08-30 | 2009-03-13 | Jagotec Ag | Formulaciones de dosis oral de liberacion controlada que comrpenden un nucleo y una o mas capas de barrera. |
WO2008068777A2 (fr) * | 2006-12-06 | 2008-06-12 | Torrent Pharmaceuticals Limited | Formulation stable de lercanidipine |
CN101784260A (zh) * | 2007-07-23 | 2010-07-21 | 法尔玛赞公司 | 包含二氢吡啶钙通道拮抗剂的药物组合物及其制备方法 |
-
2007
- 2007-07-23 CN CN200780100025A patent/CN101784260A/zh active Pending
- 2007-07-23 EP EP07786262.1A patent/EP2180883B1/fr active Active
- 2007-07-23 AU AU2007356942A patent/AU2007356942B2/en active Active
- 2007-07-23 BR BRPI0721883-4A2A patent/BRPI0721883A2/pt not_active IP Right Cessation
- 2007-07-23 NZ NZ582648A patent/NZ582648A/en unknown
- 2007-07-23 CA CA2691752A patent/CA2691752C/fr active Active
- 2007-07-23 WO PCT/EP2007/006517 patent/WO2009012791A1/fr active Application Filing
- 2007-07-23 ES ES07786262.1T patent/ES2622495T3/es active Active
- 2007-07-23 EA EA201070160A patent/EA021645B1/ru not_active IP Right Cessation
- 2007-07-23 JP JP2010517273A patent/JP5769963B2/ja not_active Expired - Fee Related
- 2007-07-23 MX MX2010000856A patent/MX2010000856A/es active IP Right Grant
- 2007-07-23 KR KR1020107001425A patent/KR101632079B1/ko active IP Right Grant
- 2007-07-23 UA UAA201001781A patent/UA97161C2/ru unknown
-
2008
- 2008-07-23 ES ES08775312.5T patent/ES2537063T3/es active Active
- 2008-07-23 UA UAA201000447A patent/UA99136C2/ru unknown
- 2008-07-23 KR KR1020107002430A patent/KR101512404B1/ko active IP Right Grant
- 2008-07-23 BR BRPI0814666A patent/BRPI0814666A2/pt not_active IP Right Cessation
- 2008-07-23 MY MYPI2010000318A patent/MY153857A/en unknown
- 2008-07-23 WO PCT/EP2008/059645 patent/WO2009013306A1/fr active Application Filing
- 2008-07-23 AU AU2008280106A patent/AU2008280106B9/en not_active Ceased
- 2008-07-23 JP JP2010517393A patent/JP2010534220A/ja active Pending
- 2008-07-23 EA EA201000220A patent/EA019614B1/ru unknown
- 2008-07-23 CN CN201410243247.6A patent/CN103976968A/zh active Pending
- 2008-07-23 EP EP20080775312 patent/EP2170295B1/fr active Active
- 2008-07-23 MX MX2010000801A patent/MX2010000801A/es active IP Right Grant
- 2008-07-23 CA CA2693233A patent/CA2693233A1/fr not_active Abandoned
- 2008-07-23 CN CN200880100075A patent/CN101801347A/zh active Pending
- 2008-07-23 NZ NZ582690A patent/NZ582690A/en not_active IP Right Cessation
-
2010
- 2010-01-08 TN TNP2010000011A patent/TN2010000011A1/fr unknown
- 2010-01-13 TN TNP2010000022A patent/TN2010000022A1/fr unknown
- 2010-01-20 CO CO10005281A patent/CO6290639A2/es not_active Application Discontinuation
- 2010-01-26 ZA ZA2010/00586A patent/ZA201000586B/en unknown
- 2010-02-17 MA MA32628A patent/MA31684B1/fr unknown
- 2010-02-18 ZA ZA2010/01176A patent/ZA201001176B/en unknown
- 2010-02-19 CR CR11285A patent/CR11285A/es unknown
- 2010-02-23 EC EC2010009984A patent/ECSP109984A/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA31684B1 (fr) | Composition pharmaceutique contenant un antagoniste des canaux calciques de type dihydropyridine et son procédé de préparation | |
MA30807B1 (fr) | Compositions pharmaceutiques. | |
MA29731B1 (fr) | Derives de pyridazinone utilises comme agonistes du recepteur de l'hormone tyroïdienne | |
MA27774A1 (fr) | Inhibiteurs de phosphatidylinositol 3-kinase | |
MA34207B1 (fr) | Inhibiteurs de la pi3 kinase et/ou du mtor | |
MA32070B1 (fr) | Dérivés hétérocycliques réunis par fusion et procédés d'utilisation associés | |
MA31283B1 (fr) | Produits dérivés de 2,3-dihydroimidazo[1,2-c]quinazoline substitués, utiles pour le traitement de troubles hyperlifératifs et de maladies associées à une angiogénèse | |
MA33636B1 (fr) | Dérivés aminopropioniques substitués comme inhibiteurs de néprilysine | |
MA30221B1 (fr) | Aryldihydro-isoquinoléinones substituées par un azacyclyle, procédé pour leur préparation et leur utilisation en tant que médicaments | |
TNSN08445A1 (fr) | Derives de triazolopyrazine utiles comme agent anticancereux | |
MA33178B1 (fr) | Pipéridines substituées comme antagonistes de ccr3 | |
MA29335B1 (fr) | Derives de n-(n-sulfonylaminomethyl) cyclopropanecarboxamide utiles pour le traitement de la douleur | |
MA35513B1 (fr) | Compositions pharmaceutiques comprenant 40 - o - ( 2 - hydroxy) éthyl - rapamycine | |
MA30766B1 (fr) | Formes de dosage pharmaceutiques orales anti-manipulation contenant un analgesique opioide | |
MA30602B1 (fr) | Modulateurs du metabolisme, et traitement de troubles au moyen de ces modulateurs | |
MA26960A1 (fr) | Sels d'un isothiazole-4-carboxamide et leur utilisation comme agent anti-hyperproliferation | |
MA30696B1 (fr) | Derives de l'acide (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)-acetique | |
TNSN08428A1 (fr) | NOUVELLE FORME d'ADMINISTRATION DU RACECADOTRIL | |
MA26739A1 (fr) | Sel mutuel d'amlodipine et d'atorvastatine, procede pour sa preparation et compositions pharmaceutiques les contenant | |
MA34313B1 (fr) | Formulation pharmaceutique sous la forme de comprimés bicouches comprenant un inhibiteur de hmg-coa réductase et d'irbésartan | |
MA31142B1 (fr) | Derives heteroaryles de pyrrolidinyl et piperdinyl cetones. | |
MA53927B1 (fr) | Composition pharmaceutique pour une administration par voie orale comprenant un dérivé d'aminopyrimidine ou son sel | |
MA31397B1 (fr) | Sels de [4(-(6-fluoro-7-méthylamino-2, 4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phényl]-5-chloro-thiophén-2-yl-sulfonylurée, formes et procédés qui leur sont associés | |
MA26741A1 (fr) | Suspensions de ziprasidone nouvelles et procede pour leur preparation. | |
MA31204B1 (fr) | Sels d'addition acides, hydrates et polymorphes d'ethylamide d'acide 5-(2,4-dihydroxy-5-isopropyl-phenyl) -4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole-3-carboxylique et preparations comprenant ces formes |